Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 698 across all filing types
Latest filing 2020-08-19 Regulatory Filings
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a research agreement between Theralase Technologies Inc. and the University of Manitoba to develop a coronavirus vaccine and therapy. It contains no financial statements, no regulatory filings, no voting results, no management or board changes, no earnings data, and no detailed financial or operational analysis. It is a corporate announcement about a research collaboration and future plans, typical of a press release. The document length is 8963 characters, which is substantial but the content is clearly a press release rather than a financial or regulatory report. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not fit into any other specific category.
2020-08-19 English
News release - English.pdf
Regulatory Filings
2020-08-17 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the recommencement of clinical study sites for a Phase II bladder cancer study by Theralase Technologies Inc. It provides details about the clinical trial status, study endpoints, and future plans. There are no financial statements, regulatory filings, or detailed financial data. The content is focused on clinical trial progress and company updates rather than financial results or governance. This type of document is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit into more specific categories like earnings release, annual report, or investor presentation.
2020-08-12 English
News release - English.pdf
Regulatory Filings
2020-07-30 English
Notice of the meeting and record date - English.pdf
Regulatory Filings
2020-07-28 English
News release - English.pdf
Regulatory Filings
2020-06-30 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.